There is very little evidenced-based data to indicate that many of the therapies described below are beneficial (or harmful), and the studies that have been performed are based on largely open-label designs and anecdotal reports. A review by the American Academy of Neurology failed to identify much evidence in support of most complementary and alternative therapies.
Highlights of current alternative and complementary therapies:
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009; 24(7):979-983.
Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004; 75(12):1672-1677.
Kim SR, Lee TY, Kim MS, Lee MC, Chung SJ. Use of complementary and alternative medicine by Korean patients with Parkinson’s disease. Clin Neurol Neurosurg. 2009; 111:156-160.
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66(7):976-982.